Similar articles

• Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

  Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM. Kwon HJ, et al. Ann Intern Med. 2003 May 20;138(10):807-11. doi: 10.7326/0003-4819-138-10-200305200-00008. Ann Intern Med. 2003. PMID: 12755552 Review.
• Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.

  Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM. Curtis JR, et al. Rheumatology (Oxford). 2007 Nov;46(11):1688-93. doi: 10.1093/rheumatology/kem212. Epub 2007 Oct 15. Rheumatology (Oxford). 2007. PMID: 17938138 Free PMC article.
• Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

  Hyrich KL, Silman AJ, Watson KD, Symmons DP. Hyrich KL, et al. Ann Rheum Dis. 2004 Dec;63(12):1538-43. doi: 10.1136/ard.2004.024737. Epub 2004 Jul 8. Ann Rheum Dis. 2004. PMID: 15242866 Free PMC article. Review.
• Inconsistencies in reporting of granulomatous infectious diseases associated with infliximab and etanercept.

  Schaible TF. Schaible TF. Clin Infect Dis. 2004 Oct 15;39(8):1255-6; author reply 1256. doi: 10.1086/424457. Clin Infect Dis. 2004. PMID: 15486858 No abstract available.
• Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.

  Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM. Lee JH, et al. Arthritis Rheum. 2002 Oct;46(10):2565-70. doi: 10.1002/art.10583. Arthritis Rheum. 2002. PMID: 12384912